ID   U266B1
AC   CVCL_0566
SY   U266-B1; U266 B1; U-266; U 266; U266; U266S; U266BL; U266 Bl; 266 Bl
DR   BTO; BTO:0001594
DR   CLO; CLO_0009457
DR   CLO; CLO_0009458
DR   EFO; EFO_0001254
DR   MCCL; MCC:0000471
DR   CLDB; cl4584
DR   CLDB; cl4609
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ArrayExpress; E-TABM-937
DR   ATCC; TIB-196
DR   BCRC; 60437
DR   BCRJ; 0240
DR   BioSample; SAMN01821605
DR   BioSample; SAMN01821669
DR   BioSample; SAMN03472935
DR   BioSample; SAMN10987866
DR   cancercelllines; CVCL_0566
DR   CCRID; 1101HUM-PUMC000684
DR   CCRID; 4201HUM-CCTCC00325
DR   CCTCC; GDC0301
DR   CCTCC; GDC0325
DR   Cell_Model_Passport; SIDM00417
DR   CGH-DB; 37-1
DR   CGH-DB; 9155-4
DR   ChEMBL-Cells; CHEMBL3308535
DR   ChEMBL-Targets; CHEMBL2366315
DR   CLS; 300259
DR   Cosmic; 720795
DR   Cosmic; 742953
DR   Cosmic; 753615
DR   Cosmic; 759903
DR   Cosmic; 759912
DR   Cosmic; 760401
DR   Cosmic; 760647
DR   Cosmic; 886087
DR   Cosmic; 888019
DR   Cosmic; 991555
DR   Cosmic; 1424220
DR   Cosmic; 1483078
DR   Cosmic; 1762463
DR   Cosmic; 1889513
DR   Cosmic; 2081409
DR   Cosmic; 2159571
DR   Cosmic; 2367281
DR   Cosmic; 2391806
DR   Cosmic; 2809754
DR   Cosmic-CLP; 753615
DR   DepMap; ACH-000626
DR   DSMZ; ACC-9
DR   DSMZCellDive; ACC-9
DR   ECACC; 85051003
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 753615
DR   GEO; GSM143345
DR   GEO; GSM545498
DR   GEO; GSM545499
DR   GEO; GSM562821
DR   GEO; GSM827442
DR   GEO; GSM887721
DR   GEO; GSM888815
DR   GEO; GSM1374970
DR   GEO; GSM1670556
DR   IARC_TP53; 361
DR   IARC_TP53; 30185
DR   IBRC; C10148
DR   IGRhCellID; U266B1
DR   IZSLER; BS TCL 233
DR   KCB; KCB 2013024YJ
DR   LiGeA; CCLE_465
DR   LINCS_LDP; LCL-2050
DR   Lonza; 106
DR   Lonza; 807
DR   NCBI_Iran; C151
DR   PharmacoDB; U266B1_1630_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0566
DR   PubChem_Cell_line; CVCL_0566
DR   Wikidata; Q54973634
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1373872;
RX   PubMed=1643757;
RX   PubMed=1720489;
RX   PubMed=2140233;
RX   PubMed=2537114;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3874327;
RX   PubMed=4097745;
RX   PubMed=4104421;
RX   PubMed=6350451;
RX   PubMed=8943038;
RX   PubMed=9685479;
RX   PubMed=10087940;
RX   PubMed=10557056;
RX   PubMed=10583232;
RX   PubMed=10936422;
RX   PubMed=11154231;
RX   PubMed=11157491;
RX   PubMed=11429052;
RX   PubMed=14555701;
RX   PubMed=15215163;
RX   PubMed=16956823;
RX   PubMed=17171682;
RX   PubMed=17229644;
RX   PubMed=17692805;
RX   PubMed=18647998;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=21173094;
RX   PubMed=22460905;
RX   PubMed=22806891;
RX   PubMed=23074853;
RX   PubMed=23992230;
RX   PubMed=25485619;
RX   PubMed=25688540;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30285677;
RX   PubMed=30545397;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=32123307;
RX   PubMed=35839778;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
WW   https://tcpaportal.org/mclp/
CC   Group: Hybridoma fusion partner cell line.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
CC   Population: Caucasian.
CC   Characteristics: Produces IgE lambda.
CC   Doubling time: 108-144 hours (PubMed=4104421); ~55 hours (DSMZ=ACC-9).
CC   HLA typing: A*02:01,03; B*07,40; C*03:04,07 (Direct_author_submission).
CC   HLA typing: A*02:01,03:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293).
CC   HLA typing: A*02:01:01;03:01:01; B*07:02:01,40:01:02; C*03:04:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,02:01:02; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRA*01:02:02,01:02:03; DRB1*03:01:01,15:01:01 (DSMZCellDive=ACC-9).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=1373872; PubMed=21173094; Cosmic-CLP; DepMap).
CC   Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (PubMed=17692805).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0%; Native American=0%; East Asian, North=2.78%; East Asian, South=0.29%; South Asian=0.45%; European, North=80.76%; European, South=15.72% (PubMed=30894373).
CC   Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C.
CC   Discontinued: BCRJ; 0240; probable.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; CCRID; CLS; Cosmic-CLP; DSMZ; ECACC; Genomics_Center_BCF_Technion; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D10S1248: 14
ST   D12S391: 18
ST   D13S317: 12
ST   D16S539: 10
ST   D18S51: 12,14
ST   D19S433: 13,15
ST   D1S1656: 12,15
ST   D21S11: 28,29
ST   D22S1045: 15,16
ST   D2S1338: 20,23
ST   D2S441: 10,11
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D6S1043: 11,17
ST   D7S820: 11,12
ST   D8S1179: 13
ST   DYS391: 10
ST   FGA: 18
ST   Penta D: 10,13
ST   Penta E: 10,12
ST   TH01: 5,7
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_JA36 ! U255
OI   CVCL_W412 ! U268
SX   Male
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 43
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer Cell Lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1373872;
RA   Mazars G.-R., Portier M., Zhang X.-G., Jourdan M., Bataille R.,
RA   Theillet C., Klein B.;
RT   "Mutations of the p53 gene in human myeloma cell lines.";
RL   Oncogene 7:1015-1018(1992).
//
RX   PubMed=1643757; DOI=10.1016/0090-1229(92)90205-3;
RA   Renz H., Or R., Domenico J., Leung D.Y.M., Gelfand E.W.;
RT   "Reciprocal regulatory effects of IL-4 on cell growth and
RT   immunoglobulin production in Ig-secreting human B-cell lines.";
RL   Clin. Immunol. Immunopathol. 64:233-241(1992).
//
RX   PubMed=1720489; DOI=10.1016/0145-2126(91)90110-f;
RA   Suzuki A., Takahashi T., Okuno Y., Fukumoto M., Fukui H.,
RA   Koishihara Y., Ohsugi Y., Ohno Y., Imura H.;
RT   "Estimation of interleukin 6 production by reverse
RT   transcriptase-polymerase chain reaction in four human myeloma cell
RT   lines.";
RL   Leuk. Res. 15:1043-1050(1991).
//
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
//
RX   PubMed=2537114; DOI=10.1182/blood.V73.2.566.566;
RA   Duperray C., Klein B., Durie B.G.M., Zhang X., Jourdan M.,
RA   Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G.M.,
RA   Bataille R.;
RT   "Phenotypic analysis of human myeloma cell lines.";
RL   Blood 73:566-572(1989).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=4097745;
RA   Nilsson K., Bennich H., Johansson S.G.O., Ponten J.;
RT   "Established immunoglobulin producing myeloma (IgE) and lymphoblastoid
RT   (IgG) cell lines from an IgE myeloma patient.";
RL   Clin. Exp. Immunol. 7:477-489(1970).
//
RX   PubMed=4104421; DOI=10.1002/ijc.2910070303;
RA   Nilsson K.;
RT   "Characteristics of established myeloma and lymphoblastoid cell lines
RT   derived from an E myeloma patient: a comparative study.";
RL   Int. J. Cancer 7:380-396(1971).
//
RX   PubMed=6350451; DOI=10.4049/jimmunol.131.3.1201;
RA   Abrams P.G., Knost J.A., Clarke G., Wilburn S., Oldham R.K.,
RA   Foon K.A.;
RT   "Determination of the optimal human cell lines for development of
RT   human hybridomas.";
RL   J. Immunol. 131:1201-1204(1983).
//
RX   PubMed=8943038; DOI=10.1073/pnas.93.24.13931;
RA   Bergsagel P.L., Chesi M., Nardini E., Brents L.A., Kirby S.L.,
RA   Kuehl W.M.;
RT   "Promiscuous translocations into immunoglobulin heavy chain switch
RT   regions in multiple myeloma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).
//
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
//
RX   PubMed=10087940; DOI=10.1016/S0165-4608(98)00157-5;
RA   Kuipers J., Vaandrager J.W., Weghuis D.O., Pearson P.L., Scheres J.,
RA   Lokhorst H.M., Clevers H.C., Bast B.J.E.G.;
RT   "Fluorescence in situ hybridization analysis shows the frequent
RT   occurrence of 14q32.3 rearrangements with involvement of
RT   immunoglobulin switch regions in myeloma cell lines.";
RL   Cancer Genet. Cytogenet. 109:99-107(1999).
//
RX   PubMed=10557056; DOI=10.1038/sj.leu.2401563;
RA   Yoshida S., Nakazawa N., Iida S., Hayami Y., Sato S., Wakita A.,
RA   Shimizu S., Taniwaki M., Ueda R.;
RT   "Detection of MUM1/IRF4-IgH fusion in multiple myeloma.";
RL   Leukemia 13:1812-1816(1999).
//
RX   PubMed=10583232; DOI=10.1046/j.1365-2141.1999.01705.x;
RA   Puthier D., Derenne S., Barille S., Moreau P., Harousseau J.-L.,
RA   Bataille R., Amiot M.;
RT   "Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.";
RL   Br. J. Haematol. 107:392-395(1999).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//
RX   PubMed=11154231; DOI=10.1182/blood.V97.2.516;
RA   Hjertner O., Hjorth-Hansen H., Borset M., Seidel C., Waage A.,
RA   Sundan A.;
RT   "Bone morphogenetic protein-4 inhibits proliferation and induces
RT   apoptosis of multiple myeloma cells.";
RL   Blood 97:516-522(2001).
//
RX   PubMed=11157491; DOI=10.1182/blood.V97.3.729;
RA   Chesi M., Brents L.A., Ely S.A., Bais C., Robbiani D.F., Mesri E.A.,
RA   Kuehl W.M., Bergsagel P.L.;
RT   "Activated fibroblast growth factor receptor 3 is an oncogene that
RT   contributes to tumor progression in multiple myeloma.";
RL   Blood 97:729-736(2001).
//
RX   PubMed=11429052; DOI=10.1111/j.1349-7006.2001.tb01142.x;
RA   Hanamura I., Iida S., Akano Y., Hayami Y., Kato M., Miura K.,
RA   Harada S., Banno S., Wakita A., Kiyoi H., Naoe T., Shimizu S.,
RA   Sonta S.-I., Nitta M., Taniwaki M., Ueda R.;
RT   "Ectopic expression of MAFB gene in human myeloma cells carrying
RT   (14;20)(q32;q11) chromosomal translocations.";
RL   Jpn. J. Cancer Res. 92:638-644(2001).
//
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
//
RX   PubMed=15215163; DOI=10.1016/S0002-9440(10)63276-2;
RA   Inoue J., Otsuki T., Hirasawa A., Imoto I., Matsuo Y., Shimizu S.,
RA   Taniwaki M., Inazawa J.;
RT   "Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be
RT   associated with drug-resistance phenotype in multiple myeloma.";
RL   Am. J. Pathol. 165:71-81(2004).
//
RX   PubMed=16956823;
RA   Bataille R., Jego G., Robillard N., Barille-Nion S., Harousseau J.-L.,
RA   Moreau P., Amiot M., Pellat-Deceunynck C.;
RT   "The phenotype of normal, reactive and malignant plasma cells.
RT   Identification of 'many and multiple myelomas' and of new targets for
RT   myeloma therapy.";
RL   Haematologica 91:1234-1240(2006).
//
RX   PubMed=17171682; DOI=10.1002/gcc.20404;
RA   Lombardi L., Poretti G., Mattioli M., Fabris S., Agnelli L.,
RA   Bicciato S., Kwee I., Rinaldi A., Ronchetti D., Verdelli D.,
RA   Lambertenghi-Deliliers G., Bertoni F., Neri A.;
RT   "Molecular characterization of human multiple myeloma cell lines by
RT   integrative genomics: insights into the biology of the disease.";
RL   Genes Chromosomes Cancer 46:226-238(2007).
//
RX   PubMed=17229644; DOI=10.3324/haematol.10300;
RA   Sanda T., Iida S., Kayukawa S., Ueda R.;
RT   "Induction of class II major histocompatibility complex expression in
RT   human multiple myeloma cells by retinoid.";
RL   Haematologica 92:115-120(2007).
//
RX   PubMed=17692805; DOI=10.1016/j.ccr.2007.07.003;
RA   Keats J.J., Fonseca R., Chesi M., Schop R., Baker A., Chng W.-J.,
RA   Van Wier S., Tiedemann R., Shi C.-X., Sebag M., Braggio E., Henry T.,
RA   Zhu Y.-X., Fogle H., Price-Troska T.L., Ahmann G.J., Mancini C.,
RA   Brents L.A., Kumar S.K., Greipp P., Dispenzieri A., Bryant B.,
RA   Mulligan G., Bruhn L., Barrett M.T., Valdez R., Trent J.M.,
RA   Stewart A.K., Carpten J.D., Bergsagel P.L.;
RT   "Promiscuous mutations activate the noncanonical NF-kappaB pathway in
RT   multiple myeloma.";
RL   Cancer Cell 12:131-144(2007).
//
RX   PubMed=18647998; DOI=10.1093/jncimonographs/lgn011;
RA   Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.;
RT   "Characterization of MYC translocations in multiple myeloma cell
RT   lines.";
RL   J. Natl. Cancer Inst. Monogr. 39:25-31(2008).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21173094; DOI=10.3324/haematol.2010.033456;
RA   Moreaux J., Klein B., Bataille R., Descamps G., Maiga S., Hose D.,
RA   Goldschmidt H., Jauch A., Reme T., Jourdan M., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "A high-risk signature for patients with multiple myeloma established
RT   from the molecular classification of human myeloma cell lines.";
RL   Haematologica 96:574-582(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22806891; DOI=10.1182/blood-2011-08-371567;
RA   Holien T., Vatsveen T.K., Hella H., Waage A., Sundan A.;
RT   "Addiction to c-MYC in multiple myeloma.";
RL   Blood 120:2450-2453(2012).
//
RX   PubMed=23074853; DOI=10.1134/S1990519X12050136;
RA   Turilova V.I., Smirnova T.D.;
RT   "Karyotypic variability of human myeloma cell lines.";
RL   Tsitologiia 54:621-636(2012).
//
RX   PubMed=23992230; DOI=10.1111/ejh.12192;
RA   Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.;
RT   "Responsiveness of cytogenetically discrete human myeloma cell lines
RT   to lenalidomide: lack of correlation with cereblon and interferon
RT   regulatory factor 4 expression levels.";
RL   Eur. J. Haematol. 91:504-513(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30545397; DOI=10.1186/s13045-018-0679-0;
RA   Tessoulin B., Moreau-Aubry A., Descamps G., Gomez-Bougie P., Maiga S.,
RA   Gaignard A., Chiron D., Menoret E., Le Gouill S., Moreau P., Amiot M.,
RA   Pellat-Deceunynck C.;
RT   "Whole-exon sequencing of human myeloma cell lines shows mutations
RT   related to myeloma patients at relapse with major hits in the DNA
RT   regulation and repair pathways.";
RL   J. Hematol. Oncol. 11:137.1-137.13(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=32123307; DOI=10.1038/s41375-020-0785-1;
RA   Sarin V., Yu K., Ferguson I.D., Gugliemini O., Nix M.A., Hann B.,
RA   Sirota M., Wiita A.P.;
RT   "Evaluating the efficacy of multiple myeloma cell lines as models for
RT   patient tumors via transcriptomic correlation analysis.";
RL   Leukemia 34:2754-2765(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//